Cytokine Blockade in Rheumatoid Arthritis

  • Marc Feldmann
  • Ravinder N. Maini
  • Jan Bondeson
  • Peter Taylor
  • Brian M. J. Foxwell
  • Fionula M. Brennan
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 490)


As we enter the 2000’s it is clear that cytokine blockade is an effective therapeutic strategy for rheumatoid arthritis. In this brief review, we will review the rationale for anti TNFa therapy, the current status of therapy and focus on the regulation of TNFa production in rheumatoid synovium. New approaches to studying TNF regulation in RA and of elucidating the controversial role of T cells in this complex disease will be described.


Rheumatoid Arthritis Tumor Necrosis Factor Receptor TNFa Production Rheumatoid Synovium Tumour Necrosis Factor mRNA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    ArendW. P.and Dayer, J. M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum33, 305–315 (1990).PubMedCrossRefGoogle Scholar
  2. 2.
    Roux-Lombard, P., Modoux, C., Vischer, T., Grassi, J. and Dayer, J. M. Inhibitors of interleukin 1 activity in synovial fluids and in cultured synovial fluid mononuclear cells.J Rheumatol19, 517–523 (1992).PubMedGoogle Scholar
  3. 3.
    Koch, A. al.Synovial tissue macrophage as a source of the chemotactic cytokine IL-8.J Immunol147, 2187–2195 (1991).PubMedGoogle Scholar
  4. 4.
    Cush, J.J. et al.Elevated interleukin-10 levels in patients with rheumatoid arthritis.Arthritis Rheum38, 96–104 (1995).PubMedCrossRefGoogle Scholar
  5. 5.
    Di Giovine, F. S., Nuki, G. and Duff, G. W. Tumour necrosis factor in synovial exudates.Ann Rheum Dis47, 768–772 (1988).PubMedCrossRefGoogle Scholar
  6. 6.
    Hopkins, S. J., Humphreys, M. and Jayson, M. I. Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1.Clin Exp Immunol72, 422–427 (1988).PubMedGoogle Scholar
  7. 7.
    Feldmann, M., Brennan, F. M. and Maini, R. N. Role of cytokines in rheumatoid arthritis.Annu Rev. Immunol.14, 397–440 (1996).PubMedCrossRefGoogle Scholar
  8. 8.
    Buchan, G., Barrett, K., Turner, M., Chantry, D., Maini, R. N. and Feldmann, M. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-la.Clin Exp Immunol73, 449–455 (1988).PubMedGoogle Scholar
  9. 9.
    Brennan, F. M., Chantry, D., Jackson, A., Maini, R. and Feldmann, M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-I production in rheumatoid arthritis.Lancet2, 244–7 (1989).PubMedCrossRefGoogle Scholar
  10. 10.
    Brennan, F. M., Maini, R. N. and Feldmann, M. TNFaα—a pivotal role in rheumatoid arthritis?Br J Rheumatol31, 293–298 (1992).PubMedCrossRefGoogle Scholar
  11. 11.
    Feldmann, al.Cytokine production in the rheumatoid joint: implications for treatment.Ann Rheum Dis49, 480–486 (1990).PubMedGoogle Scholar
  12. 12.
    Chu, C. Q., Field, M., Feldmann, M. and Maini, R. N. Localization of tumor necrosis factor a in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis.Arthritis Rheum34, 1125–1132 (1991).PubMedCrossRefGoogle Scholar
  13. Deleuran, B. W., Chu, C.Q., Field, M., Brennan, F.M., Mitchell, T., Feldmann, M. and Maini, R.N. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha.Arthritis Rheum35, 1170–1178 (1992).PubMedCrossRefGoogle Scholar
  14. 14.
    Williams, R. O., Feldmann, M. and Maini, R. N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.Proc Natl Acad Sci USA89, 9784–9788 (1992).PubMedCrossRefGoogle Scholar
  15. 15.
    Thorbecke, G. J., Shah, R., Leu, C. H., Kuruvilla, A. P., Hardison, A. M. and Palladino, M. A. Involvement of endogenous tumour necrosis factor a and transforming growth factor ß during induction of collagen type II arthritis in mice.Proc Natl Acad Sci USA89, 7375–7379 (1992).PubMedCrossRefGoogle Scholar
  16. 16.
    Elliott, M. J., Maini, R.N., Feldmann, M., Long-Fox, A., Charles, P., Katsikis, P., Brennan, R.M., Walker, J., Bijl, H., Ghrayeb, J. and Woody, J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.Arthritis Rheum36, 1681–90 (1993).PubMedCrossRefGoogle Scholar
  17. 17.
    Elliott, M. J., Maini, R.N., Feldmann, M., Kalden, J.R., Antoni, C., Smolen, J.S., Leeb, B., Breedveld, F.C., Macfarlane, J.D., Bijl, H. and Woody, J.N. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.Lancet344, 1105–10 (1994).PubMedCrossRefGoogle Scholar
  18. 18.
    Maini, R.N., Breedveld, F.C., Kalden, J.R., Smolen, J.S., Davis, D., Macfarlane, J.D., Antoni, C., Leeb, B., Elliott, M.J., Woody, J.N., Schaible, T.F. and Feldmann, M. Randomized placebo-controlled trial of multiple intravenous infusions of anti-TNFa monoclonal antibody with or without weekly methotrexate in rheumatoid arthritis.Arthritis Rheum.41, 1552–1563 (1998).PubMedCrossRefGoogle Scholar
  19. Maini, R. N., William, St., Clair, E., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., Lipsky, P. Randomised phase III trial of infliximab (chimeric anti-TNFa monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate.Lancet354, 1932–1940.CrossRefGoogle Scholar
  20. 20.
    Rankin, E. C., Choy, E.H.S., Kassimos, D., Soowith, M., Kingsley, G., Isenberg, D.A. and Panayi, G.S. A double blind, placebo-controlled, ascending dose trial of the recombinant humanised anti-TNFa antibody CDP571 in patients with rheumatoid arthritis (RA): A preliminary report.Arthritis Rheum37, S295 (1994).Google Scholar
  21. 21.
    Moreland, L.W., Baumgartner, S.W., Schiff, M.H., Tindall, E.A., Fleischmann, R.M., Weaver, A.L., Ettlinger, R.E., Cohen, S., Koopman, W.J., Mohler, K., Widmer, M.B. and Blosch, C.M. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)Fc fusion protein.New England Journal of Medicine337, 141–147 (1997).PubMedCrossRefGoogle Scholar
  22. 22.
    Huang, S., Endo, R. I. and Nemerow, G. R. Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery.J Virol69, 2257–2263 (1995).PubMedGoogle Scholar
  23. 23.
    Haddada, H., Lopez, M., Martinache, C., Ragot, T., Abina, M. A. and Perricaudet, M. Efficient adenovirus-mediated gene transfer into human blood monocyte derived macrophages.Biochem Biophys Res Commun195, 1174–1183 (1993).CrossRefGoogle Scholar
  24. 24.
    Foxwell, B. M. J. Brown, K., Bondeson, J., Clarke, C. de Martin, R., Brennan, F.M. and Feldmann, M.. Efficient adenoviral infection with IxBa reveals that TNFa production in rheumatoid arthritis is NF-x13 dependent.Proc Natl Acad Sci USA95, 8211–8215 (1998).Google Scholar
  25. 25.
    Bondeson, J., Brown, K. A., Brennan, F. M., Foxwell, B. M. J. and Feldmann, M. Selective regulation of cytokine induction by adenoviral gene transfer of IxBa into human macrophages: LPS-induced but not zymosan induced, pro-inflammatory cytokines are inhibited, but IL-10 is NF-xb independent.Jlmmunol162, 2939–2945 (1999).Google Scholar
  26. 26.
    Hayes, A. L., Smith, C., Foxwell, B. M. and Brennan, F. M. CD45-induced tumor necrosis factor alpha production in monocytes is phosphatidylinositol 3-kinasedependent and nuclear factor-kappa B- independent.JBiol Chem274, 33455–61 (1999)CrossRefGoogle Scholar
  27. 27.
    Amer, E. C., Pratta, M.A., Decicco, C.P., Xue, C.B., Newton, R.C., Trzaskos, J.M., Magolda, R.L. and Tororella, M.D. Aggrecanase. A target for the design of inhibitors of cartilage degradation.Ann NY Acad Sci878, 92–107 (1999).CrossRefGoogle Scholar
  28. 28.
    Bondeson, J., Foxwell, B., Brennan, F. and Feldmann, M. Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators.Proc Natl Acad Sci USA96, 5668–73 (1999).PubMedCrossRefGoogle Scholar
  29. 29.
    Zandi, E., Rothwarf, D. M., Delhase, M., Hayakawa, M. and Karin, M. The IxB kinase complex (IKK) contains two kinase subunits, IKKa and IKKß, necessary for IKB phosphorylation and NF-KB activation.Cell91, 243–252 (1997).PubMedCrossRefGoogle Scholar
  30. 30.
    Regnier, C. H., Song, H.-Y., Gao, X., Goeddel, D. V., Cao, Z. and Rothe, M. Identification and characterization of an IxB kinase.Cell90, 373–383 (1997).PubMedCrossRefGoogle Scholar
  31. 31.
    Wallach, D., Varfolomeev, E. E., Malinin, N. L., Goltsev, Y. V., Kovalenko..A.V and Boldin, M. P. Tumor necrosis factor receptor and Fas signaling mechanisms.Annu Rev Immunol17, 331–367 (1999).PubMedCrossRefGoogle Scholar
  32. 32.
    Makarov, S. S., Johnston, W.N., Olsen, J.C., Watson, J.M., Mondal, K., Rinehart, C. and Haskill, J.S. NF-xB as a target for anti-inflammatory gene therapy: suppression of inflammatory responses in monocytic and stromal cells by stable gene transfer of IKBa cDNA.Gene Therapy4, 846–852 (1997).PubMedCrossRefGoogle Scholar
  33. 33.
    Falta, M. T. and Kotzin, B. L. in T Cells in Arthritis (eds Miossec, P., van den Berg, W. B. and Firestein, G. S.) 201–231 (Birkhauser Verlag, Basel, 1998).CrossRefGoogle Scholar
  34. 34.
    Firestein, G. S. and Zvaifler, N. J. How important are T cells in chronic rheumatoid synovitis?Arthritis Rheum33, 768–773 (1990).PubMedCrossRefGoogle Scholar
  35. 35.
    Miossec, P., van den Berg, W. B. and Firestein, G. S. in Progress in Inflammation Research (ed Farnham, M. J.) 236 (Birkhauser, Basel, 1998).Google Scholar
  36. 36.
    Tugwell, P., Bombardier, C., Gent, M., Bennett, K.J., Bensen, W.G. Klinkhoff, A.V., Kraag, G.R., Ludwin, D. and Roberts, R.S. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis.Lancet335, 1051–1055 (1990).PubMedCrossRefGoogle Scholar
  37. 37.
    Isler, P., Vey, E., Zhang, J. H. and Dayer, J. M. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69.Eur. Cytokine Netw.4, 15–23 (1993).PubMedGoogle Scholar
  38. 38.
    Brennan, F. M., Hayes, A. L., Ciesielski, C. J., Foxwell, B. M. J. and Feldmann, M. Cytokine activated T cells are important in TNFa synthesis in rheumatoid arthritis: P13 kinase and NF-KB pathways discriminate between cytokine and TCR activated T cells.Nature Medicinein press (2000).Google Scholar
  39. 39.
    Unutmaz, D., Pileri, P. and Abrignani, S. Antigen-independent activation of naïve and memory resting T cells by a cytokine combination.J Exp Med180, 1159–1164 (1994).PubMedCrossRefGoogle Scholar
  40. 40.
    Sebbag, M., Parry, S. L., Brennan, F. M. and Feldmann, M. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of TNFa but not IL-10: possible relevance to pathophysiology of rheumatoid arthritis.Eur J Immunol27, 624–632 (1997).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Marc Feldmann
    • 1
  • Ravinder N. Maini
    • 1
  • Jan Bondeson
    • 1
  • Peter Taylor
    • 1
  • Brian M. J. Foxwell
    • 1
  • Fionula M. Brennan
    • 1
  1. 1.Kennedy Institute of RheumatologyHammersmith, LondonUK

Personalised recommendations